University of Texas Texas AM Investment Management Co. Makes New $503,000 Investment in BioCryst Pharmaceuticals, Inc. $BCRX

University of Texas Texas AM Investment Management Co. purchased a new position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 64,507 shares of the biotechnology company’s stock, valued at approximately $503,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Phocas Financial Corp. acquired a new stake in shares of BioCryst Pharmaceuticals during the fourth quarter worth approximately $1,956,000. Vanguard Group Inc. increased its holdings in shares of BioCryst Pharmaceuticals by 6.1% during the third quarter. Vanguard Group Inc. now owns 21,790,881 shares of the biotechnology company’s stock worth $165,393,000 after buying an additional 1,246,633 shares in the last quarter. Aberdeen Group plc acquired a new stake in shares of BioCryst Pharmaceuticals during the fourth quarter worth approximately $7,126,000. Public Sector Pension Investment Board acquired a new stake in shares of BioCryst Pharmaceuticals during the third quarter worth approximately $2,010,000. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al increased its holdings in shares of BioCryst Pharmaceuticals by 106.5% during the fourth quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 233,354 shares of the biotechnology company’s stock worth $1,820,000 after buying an additional 120,350 shares in the last quarter. Institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Price Performance

Shares of BioCryst Pharmaceuticals stock opened at $8.92 on Wednesday. The firm has a market cap of $2.27 billion, a P/E ratio of -5.01 and a beta of 0.57. The firm has a 50 day simple moving average of $8.93 and a 200 day simple moving average of $8.15. BioCryst Pharmaceuticals, Inc. has a fifty-two week low of $6.00 and a fifty-two week high of $10.32.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported ($2.98) earnings per share for the quarter, missing analysts’ consensus estimates of $0.06 by ($3.04). The company had revenue of $156.41 million during the quarter, compared to analyst estimates of $151.12 million. BioCryst Pharmaceuticals had a negative net margin of 51.71% and a negative return on equity of 76.36%. The business’s revenue for the quarter was up 7.5% on a year-over-year basis. During the same period in the prior year, the business earned $0.20 EPS. On average, sell-side analysts expect that BioCryst Pharmaceuticals, Inc. will post -2.66 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on BCRX. Weiss Ratings reaffirmed a “hold (c)” rating on shares of BioCryst Pharmaceuticals in a report on Monday, June 1st. Needham & Company LLC dropped their price objective on shares of BioCryst Pharmaceuticals from $18.00 to $16.00 and set a “buy” rating for the company in a report on Wednesday, May 6th. Evercore began coverage on shares of BioCryst Pharmaceuticals in a report on Wednesday, February 18th. They set an “outperform” rating and a $17.00 price objective for the company. Wedbush dropped their price objective on shares of BioCryst Pharmaceuticals from $22.00 to $21.00 and set an “outperform” rating for the company in a report on Thursday, May 7th. Finally, Wall Street Zen lowered shares of BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 9th. Nine investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $20.70.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.